Riluzole Reverses Blood–Testis Barrier Loss to Rescue Chemotherapy–Induced Male Infertility by Binding to TRPC
Cells · 2024
DOI: 10.3390/cells13232016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Rufei Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, Jinan University, Guangzhou 510632, China. Hauptthemen laut MEDLINE: Riluzole, Blood-Testis Barrier, Infertility, Male. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, Guangzhou Key R&D Program.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Cancer treatments, including cytotoxic therapy, often result in male infertility, necessitating the development of safe and effective strategies to preserve male reproductive potential during chemotherapy. Notably, our study uncovers the potential of repurposing riluzole, an FDA-approved drug for amyotrophic lateral sclerosis (ALS), in enhancing spermatogenesis. Hence, this research aims to explore the feasibility of utilizing riluzole to alleviate male infertility induced by busulfan (BSF), a commonly used chemotherapy drug. We established a BSF-induced oligospermia model in 4-week-old male mice and found that riluzole could effectively counter the detrimental effects of BSF on sperm production in mice with oligospermia. By restoring blood–testis barrier (BTB) functionality, riluzole improves sperm quality and reduces testicular atrophy. Through transcriptomic and molecular docking analyses, we identify transient receptor potential canonical subfamily member 5 (TRPC5) as a potential target for riluzole-mediated regulation of blood–testis barrier function. These findings propose riluzole as a promising therapeutic option for chemotherapy-induced male infertility, thereby addressing the fertility challenges associated with cancer treatments. Moreover, repurposing riluzole could streamline the drug development process, providing a cost-effective approach with reduced risk compared to developing entirely new drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology, Jinan University, Guangzhou 510632, China.
- Guangdong Province Key Laboratory of Bioengineering Medicine, Guangzhou 510632, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Guangzhou Key R&D Program
- Kea-Area Research and Development Program of Guangdong Province
- Guangzhou Key R&D Program
Zitieren
APA
Huang, R., Xia, H., Lin, W., Wang, Z., Li, L., Deng, J., Ye, T., Li, Z., Yang, Y., & Huang, Y. (2024). Riluzole Reverses Blood–Testis Barrier Loss to Rescue Chemotherapy–Induced Male Infertility by Binding to TRPC. Cells. https://doi.org/10.3390/cells13232016
Vancouver
Huang R, Xia H, Lin W, Wang Z, Li L, Deng J, et al. Riluzole Reverses Blood–Testis Barrier Loss to Rescue Chemotherapy–Induced Male Infertility by Binding to TRPC. Cells. 2024. doi:10.3390/cells13232016
BibTeX
@article{Huang2024,
author = {Huang, Rufei and Xia, Huan and Lin, Wanqing and Wang, Zhaoyang and Li, Lu and Deng, Jingxian and Ye, Tao and Li, Ziyi and Yang, Yan and Huang, Yadong},
title = {Riluzole Reverses Blood–Testis Barrier Loss to Rescue Chemotherapy–Induced Male Infertility by Binding to TRPC},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13232016}
}
EUVIMED